A5011203707- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- Pancreatic and Hepatic Oncology Research
- Mesenchymal stem cell research
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Cancer-related Molecular Pathways
- 3D Printing in Biomedical Research
- RNA modifications and cancer
- Osteoarthritis Treatment and Mechanisms
- Glioma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Autophagy in Disease and Therapy
- vaccines and immunoinformatics approaches
- Electrospun Nanofibers in Biomedical Applications
- Extracellular vesicles in disease
- Periodontal Regeneration and Treatments
Kanazawa Medical University Hospital
2020-2023
Kanazawa Medical University
2018-2023
Shinshu University Hospital
2014-2017
Nara Institute of Science and Technology
2008
OBJECT Dendritic cell (DC)-based vaccination is considered a potentially effective therapy against advanced cancer. The authors conducted Phase I study to investigate the safety and immunomonitoring of Wilms’ tumor 1 (WT1)-pulsed DC for patients with relapsed malignant glioma. METHODS WT1-pulsed and/or autologous lysate-pulsed was performed in gliomas. Approximately × 10 7 2 pulsed DCs loaded WT1 peptide antigen lysate were intradermally injected into axillary areas OK-432, streptococcal...
Background/Aim: Wilms9 tumor 1 (WT1) is a tumor-associated antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine combination with chemotherapy patients surgically resected pancreatic Patients and Methods: Eight resectable cancer undergoing surgery either combined S-1 or plus gemcitabine therapy were enrolled. Immunohistochemical analysis WT1 was performed 34 cases Results: No serious side-effects observed, except grade I fever five...
Despite significant recent advances in the development of immune checkpoint inhibitors, treatment advanced colorectal cancer involving metastasis to distant organs remains challenging. We conducted a phase I study investigate safety and immunogenicity Wilms' tumor (WT1) class I/II peptides-pulsed dendritic cell DC vaccination for patients with cancer. Standard comprising surgical resection chemotherapy was followed by one course seven biweekly administrations 1-2 × 10⁷ DCs KE OK-432...
Despite recent advances in cancer immunotherapy and the development of various assays for T cell assessment, a lack universal standards within immune monitoring remains. The objective this study was to evaluate enzyme-linked immunosorbent spot (ELISpot) assay comparison with major histocompatibility complex-tetramer analysis context dendritic (DC)-based immunotherapy.The ELISpot performed on peripheral blood mononuclear cells assess reproducibility, daily precision, linearity using...
Given the recent advancements of immune checkpoint inhibitors, there is considerable interest in cancer immunotherapy provided through dendritic cell (DC)-based vaccination. Although many studies have been conducted to determine potency DC vaccines against cancer, clinical outcomes are not yet optimal, and further improvement necessary. In this study, we evaluated potential ability human platelet lysate (HPL) produce interferon-α-induced DCs (IFN-DCs). presence HPL, IFN-DCs (HPL-IFN-DCs)...
Background/Aim: Wilms9 tumor 1 (WT1) peptide-based vaccination has been reported for its potential usefulness in targeting several cancers. The adjuvant drug OK-432 is known to have potent immunomodulation and therapeutic properties when applied cancer treatment may, thus, be important trigger the appropriate immunological response paediatric patients with a solid that are vaccinated WT1 peptide. Patients Methods: Paediatric were peptide once every 2 weeks, total of seven times. Results: Of...
Abstract Active human dendritic cells (DCs), which efficiently induce immune responses through their functions as antigen-presenting cells, exhibit direct anti-tumour killing activity in response to some pathogens and cytokines. These tumour abilities may provide a breakthrough cancer immunotherapy. However, the mechanisms underlying this killer DC have not been fully proven, despite establishment of interferon-α (IFN-α)-generated DCs (IFN-DCs). Here mature IFN-DCs (mIFN-DCs), generated from...
Significant recent advances in cancer immunotherapeutics include the vaccination of patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, yield autologous monocyte-derived DCs varies each patient. Priming a low dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16-18 h prior apheresis resulted 50% more harvested monocytes,...
With recent advances in cancer vaccination therapy targeting tumor-associated antigens (TAAs), dendritic cells (DCs) are considered to play a central role as cell-based drug delivery system the bioactive immune environment. Ex vivo generation of monocyte-derived DCs has been conventionally applied adherent manufacturing systems with separate loading TAAs before clinical use. We developed pre-pulsed Wilms' tumor (WT1) peptides low-adhesion culture maturation (WT1-DCs). Quality tests...
The ARF transcript produces two proteins, the full‐length ARF, p19 , and a short mitochondrial version, smARF. To explore functional difference between two, we generated GFP‐fused expression vectors for each protein introduced them into NIH3T3 murine fibroblasts, which sustains global deletion in INK4a locus but contains p53 gene. GFP‐p19 was located within nucleolus as previously reported, whereas GFP‐smARF detected mainly nucleoplasm. induced cell death although to slightly lesser extent...
Dendritic cells (DCs), which are the most powerful antigen-presenting cells, activate innate and adaptive immune responses. Wilms' tumor 1 (WT1) is a tumor-associated antigen that frequently expressed in many human cancers including gliomas therefore potential target of immunotherapy for malignant gliomas. We report two cases with advanced glioma were treated clinical study DC-based targeting WT1. In patients glioma, initial standard treatment failed, disease progressed. Subsequent...
Abstract As the sentinels of innate and adaptive immune system, dendritic cells (DCs) have been considered to hold a great promise for medical application. Among diverse types DCs, monocyte‐derived DCs (mo‐DCs) generated in vitro most commonly employed. We improving culture protocol devised produce mature interferon‐α‐induced (IFN‐DCs), hereinafter called (mat)IFN‐DCs. While exploring relationship between expression CD56 cytotoxic activity (mat)IFN‐DCs, we unexpectedly found that sorting...
Osteoarthritis (OA) is an irreversible degenerative condition causing bone deformation in the joints and articular cartilage degeneration with chronic pain impaired movement. Adipose-derived stem cell (ADSC) or crushed adipose tissue injection into joint cavity reportedly improve knee function symptoms, including pain. Stem spheroids may be promising treatment options due to their anti-inflammatory enhanced regeneration/repair effects. Herein, form human ADSC spheroids, we used first...
Human dendritic cell (DC) dexosomes were evaluated for their function and preclinical validation vaccines. Dexosomes are small DC-secreted vesicles that contain absorbing immune signals. Vaccine manufacturing requires a significant number of monocyte-derived DCs (Mo-DCs) from donor blood; thus, Mo-DC expected to serve as novel materials cancer vaccination. In this study, we characterized potential dexosome model using immature mature MUTZ3-derived (M-imIL-4-DC, M-imIFN-DC, M-mIL-4-DC,...
Significant recent advances in cancer immunotherapeutics include the vaccination of patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, yield autologous monocyte-derived DCs varies each patient. Priming a low dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16–18 h prior apheresis resulted 50% more harvested...
Dendritic cell (DC) vaccines for cancer immunotherapy have been actively developed to improve clinical efficacy. In our previous report, monocyte−derived DCs induced by interleukin (IL)−4 with a low−adherence dish (low−adherent IL-4−DCs: la−IL-4−DCs) improved the yield and viability, as well relatively prolonged survival in vitro, compared IL-4−DCs using an adherent culture protocol. However, la−IL-4−DCs exhibit remarkable cluster formation display heterogeneous immature phenotypes....
Malignant pleural effusion (MPE) provides a liquid tumor microenvironment model that includes cancer cells and immune cells. However, the characteristics of antigen-specific CD8+ T have not been investigated in detail. Here, we analyzed MPE samples taken from patient with pancreatic who received dendritic cell vaccine targeting Wilms' Tumor 1 (WT1) antigen over disease course (two points at MPE1st 2nd, two months after MPE1st). Epithelial adhesion molecule (EpCAM)+ (PD-L1- or immunoglobulin...
Research and development of personalized cancer vaccines as precision medicine are ongoing. We predicted human leukocyte antigen (HLA)-compatible candidate peptides based on patient-specific genomic profiles performed a Phase I clinical trial for the safety tolerability with platelet lysate-induced antigen-presenting cells (HPL-APCs) from peripheral monocytes. Among five enrolled patients, two patients completed six doses per course (2–3 × 107 dose), an interim analysis was immune response....